SynVivo

SynVivo is a private company, founded in 2009 and headquartered in Huntsville, Alabama, that has established itself as a leader in the organ-on-a-chip (OoC) sector. It commercializes a portfolio of validated, ready-to-use microfluidic platforms (e.g., SynBBB, SynTumor, SynRAM) that mimic vascularized human tissue for predictive preclinical testing. Its business model combines product sales (chips, instruments, accessories) with fee-for-service offerings in screening and assay development, positioning it as a critical tools and services provider enabling the pharmaceutical industry's shift towards New Approach Methodologies (NAMs). The company is in a revenue-generating stage, serving academic, biotech, and pharma researchers.

Proprietary microfluidic organ-on-a-chip platforms that create 3D, vascularized human tissue models with dynamic flow and shear stress. The technology enables co-culture of multiple cell types in a physiologically relevant architecture for real-time analysis of cellular behavior, drug delivery, and therapeutic response.

SynVivo competes in the rapidly growing organ-on-a-chip market against companies like Emulate, Inc., Mimetas, CN Bio, and TissUse, as well as academic spinoffs. Its key differentiator is its focus on engineered 3D microvascular networks with dynamic flow, which provides a more physiologically complete model compared to some channel-based systems. Competition is based on technological fidelity, ease of use, model validation, price, and the breadth of applications and services offered.